tazobactam has been researched along with meropenem in 130 studies
| Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (meropenem) | Trials (meropenem) | Recent Studies (post-2010) (meropenem) |
|---|---|---|---|---|---|
| 1,327 | 153 | 694 | 3,803 | 284 | 2,253 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (2.31) | 18.2507 |
| 2000's | 19 (14.62) | 29.6817 |
| 2010's | 55 (42.31) | 24.3611 |
| 2020's | 53 (40.77) | 2.80 |
| Authors | Studies |
|---|---|
| Cattoir, V; Corvec, S; Drugeon, H; Faccone, D; Galas, M; Mugnier, P; Nordmann, P; Pasteran, F; Petroni, A; Poirel, L; Rapoport, M | 1 |
| Amicosante, G; Caporale, B; Celenza, G; Docquier, JD; Mezzatesta, M; Pellegrini, C; Perilli, M; Rossolini, GM; Stefani, S | 1 |
| Correia, A; Domingues, MR; Domingues, P; Fonseca, F; Henriques, I; Saavedra, MJ; Samyn, B; Sarmento, AC; van Beeumen, J | 1 |
| Bonnet, R; Neuwirth, C; Robin, F; Siebor, E | 1 |
| Courvalin, P; Dupêchez, M; Galimand, M; Lambert, T; Meziane-Cherif, D | 1 |
| Castanheira, M; Samuelsen, Ø; Spencer, J; Walsh, TR | 1 |
| Cauda, R; D'Inzeo, T; De Pascale, G; Fadda, G; Fiori, B; Leone, F; Rossi, M; Sali, M; Sanguinetti, M; Spanu, T; Trecarichi, EM; Tumbarello, M | 1 |
| Nordmann, P; Plésiat, P; Poirel, L; Rodriguez-Martinez, JM | 1 |
| Kirikae, T; Kitao, T; Miyoshi-Akiyama, T | 1 |
| Ghori, S; Griggs, DJ; Johnson, MM; Mott, A; Peake, L; Piddock, LJ | 1 |
| Girlich, D; Nordmann, P; Poirel, L | 1 |
| Kotsakis, SD; Legakis, NJ; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
| Choi, JY; Ko, KS; Lee, MY; Park, YK; Peck, KR; Rhee, JY; Shin, JY; Song, JH | 1 |
| Bonomo, RA; Distler, AM; Endimiani, A; Hornick, JM; Hujer, AM; Hujer, KM; Papp-Wallace, KM; Taracila, M | 1 |
| Kotsakis, SD; Miriagou, V; Tzelepi, E; Tzouvelekis, LS | 1 |
| Abendroth, J; Atkins, K; Boyer, SH; Clifton, MC; Dudley, MN; Durso, S; Griffith, DC; Hecker, SJ; Hirst, GC; King, P; Lomovskaya, O; Loutit, JS; Morgan, EE; Potts, KT; Raymond, A; Reddy, KR; Sabet, M; Sun, D; Tarazi, Z; Totrov, M; Tsivkovski, R | 1 |
| Benvenuti, M; Burns, CJ; Chu, GH; Cusick, SM; Daigle, DM; De Luca, F; Docquier, JD; Hamrick, JC; Jackson, RW; Liu, B; Mangani, S; McGarry, D; Pevear, DC; Pozzi, C; Trout, REL; Weiss, WJ; Xerri, L | 1 |
| Chen, HY; Livermore, DM | 1 |
| Babini, GS; Bates, J; Livermore, DM; Palepou, MF; Woodford, N | 1 |
| Allerberger, F; Feierl, G; Hirschl, A; Krause, R; Mittermayer, H; Reisinger, EC; Wendelin, I | 1 |
| Jones, RN; Mutnick, AH; Turner, PJ | 1 |
| Kotapati, S; Kuti, JL; Nicolau, DP; Nightingale, CH | 1 |
| Burgess, DS; Hall, RG | 1 |
| Aksoylar, S; Cetingül, N; Kansoy, S; Kantar, M; Karapinar, D; Kavakli, K | 1 |
| Jakoniuk, P; Leszczyńska, K; Sacha, PT; Wieczorek, P; Zalewska, M | 1 |
| Bellaire, T; Cornely, OA; Dörken, B; Einsele, H; Krause, S; Kubin, T; Maschmeyer, G; Reich, G; Sandherr, M; Thiel, E | 1 |
| Aydogdu, I; Ersoy, Y; Kaya, E; Kuku, I; Serefhanoglu, K; Serefhanoglu, S | 1 |
| Hashikita, G; Kawakami, S; Kobayashi, S; Maesaki, S; Nagasawa, M; Okabe, T; Sasaki, K; Shibuya, S; Suzuki, N; Takayama, S; Uchida, T; Watanabe, M; Yamaguchi, T | 1 |
| Albertí, S; Juan, C; Mulet, X; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Arias, MJ; de la Torre, A; Díaz, JA; Hernández, AP; Silva, E | 1 |
| De Backer, D; Delattre, I; Dugernier, T; Jacobs, F; Laterre, PF; Layeux, B; Spapen, H; Taccone, FS; Vincent, JL; Wallemacq, P; Wittebole, X | 1 |
| Buyle, F; Claus, B; Robays, H; Vogelaers, D | 1 |
| Clarke, MJ; Edwards, SJ; Wordsworth, S | 1 |
| Bethel, CR; Bonnet, R; Bonomo, RA; Distler, AM; Endimiani, A; Hujer, AM; Hujer, KM; Papp-Wallace, K; Shyr, T; Taracila, M; Thomson, JM | 1 |
| Antunes, NT; Frase, H; Toth, M; Vakulenko, SB; Vakulenko, V | 1 |
| Bellomo, R; Cole, L; Lipman, J; Liu, X; Nair, P; Roberts, DM; Roberts, JA; Roberts, MS | 1 |
| Beumier, M; Cotton, F; De Backer, D; Hites, M; Jacobs, F; Lorent, S; Roisin, S; Seyler, L; Surin, R; Taccone, FS; Vincent, JL; Wolff, F | 1 |
| Arakawa, S; Fujisawa, M; Miyake, H; Shigemura, K; Tanaka, K | 1 |
| Bruchmann, S; Cabot, G; Haussler, S; Juan, C; Moyà, B; Mulet, X; Oliver, A; Zamorano, L | 1 |
| Friedland, I; Hershberger, E; Lucasti, C; Miller, B; Solomkin, J; Steenbergen, J; Yankelev, S | 1 |
| Bandettini, R; Barco, S; Cangemi, G; Castagnola, E; Maffia, A; Tripodi, G | 1 |
| Frey, L; Maier, B; Suhr, A; Teupser, D; Vogeser, M; Zander, J; Zoller, M | 1 |
| Chong, Y; Jeong, SH; Kim, M; Kim, WH; Lee, K; Lee, Y; Seo, YH; Yim, J; Yong, D | 1 |
| Castanheira, M; Farrell, DJ; Flamm, RK; Jones, RN; Mendes, RE; Sader, HS | 1 |
| Ballard, A; Biddy, BA; Bouley, R; Burnham, CA; Chang, M; Dantas, G; Gonzales, PR; Mobashery, S; Pesesky, MW; Schroeder, VA; Suckow, MA; Wolter, WR | 1 |
| Alyousef, AA; Alzahrani, AJ; Krishnappa, LG; Marie, MA; Mubaraki, MA | 1 |
| Alkrouk, A; Buehrle, DJ; Chen, L; Clancy, CJ; Hao, B; Kreiswirth, BN; Nguyen, MH; Potoski, BA; Press, EG; Shields, RK | 1 |
| Banerjee, R; Boyce, TG; Cunningham, SA; Hasassri, ME; Jeraldo, PR; Kaye, KS; Norgan, AP; Patel, R; Pogue, JM; Weissman, SJ | 1 |
| Bliss, CA; Cloutier, D; Hershberger, E; Huntington, JA; Kaye, KS; Miller, B; Paterson, DL; Popejoy, MW; Steenbergen, JN; Umeh, O | 1 |
| Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J | 1 |
| Compain, F; Grohs, P; Kaibi, I; Lavollay, M; Mainardi, JL; Morand, P; Podglajen, I; Taieb, G | 1 |
| Chesnel, L; Howland, K; Jacqueline, C | 1 |
| Grupper, M; Nicolau, DP; Sutherland, C | 1 |
| Mueller, BA; Shaw, AR | 1 |
| Ali, I; Shabbir, M | 1 |
| Goodlet, KJ; Nailor, MD; Nicolau, DP | 1 |
| Hindler, JA; Humphries, RM; Miller, SA; Wong-Beringer, A | 1 |
| Coburn, B; Daneman, N; MacFadden, DR | 1 |
| Kollef, MH; Micek, ST; Vazquez Guillamet, MC; Vazquez, R | 1 |
| Castanheira, M; Flamm, RK; Pfaller, MA; Shortridge, D | 1 |
| Lasco, TM; Ledesma, KR; Skoglund, E; Tam, VH | 1 |
| Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS; Shortridge, D | 1 |
| An, G; Bach, T; D'Cunha, R; Li, P; Nalbant, D; Winokur, P; Young, BA; Zhang, J | 2 |
| Farkas, A; Heil, EL; Nicolau, DP; Roberts, JA; Thom, KA | 1 |
| Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
| Gutiérrez-Gutiérrez, B; Kahlmeter, G; Rodríguez-Baño, J | 1 |
| Berdaï, D; Boyer, A; Prevel, R | 1 |
| Blevins, AM; Juang, P; Kollef, M; Lashinsky, JN; McCammon, C; Micek, S | 1 |
| Hsu, AJ; Tamma, PD | 1 |
| Avery, LM; Nicolau, DP; Sutherland, CA | 1 |
| Albanèse, J; Bornet, C; Curti, C; Fersing, C; Guinard, B; Lamy, E; Mathias, F; Primas, N; Souab, HK; Vanelle, P | 1 |
| Doogue, M; Jensen, BP; Mortensen, JS; Zhang, M | 1 |
| Hoban, DJ; Lob, SH; Motyl, MR; Sahm, DF; Young, K | 1 |
| Papp-Wallace, KM | 1 |
| Bruno, CJ; Butterton, JR; Huntington, JA; Kivistik, Ü; Kollef, MH; Lin, G; Martin-Loeches, I; Nováček, M; Réa-Neto, Á; Rhee, EG; Shime, N; Timsit, JF; Wunderink, RG; Yu, B | 1 |
| Kalil, AC; Zavascki, AP | 1 |
| Caverly, LJ; Huang, DB; Kalikin, LM; LiPuma, JJ; Spilker, T; Stillwell, T; Young, C | 1 |
| Burnham, CD; Dantas, G; Thänert, R; Yoneda, A | 1 |
| Bruno, CJ; Kollef, MH; Réa-Neto, Á; Rhee, EG; Wunderink, RG | 1 |
| Lai, CC; Tang, HJ | 1 |
| Baillon-Plot, N; Bassetti, M; Charbonneau, C; Di Virgilio, R; Eckmann, C; Kongnakorn, T; Tichy, E | 1 |
| Millar, BC; Moore, JE; Moore, RE | 1 |
| Gatermann, SG; Körber-Irrgang, B; Korte-Berwanger, M; Kresken, M; Pfennigwerth, N; Seifert, H | 1 |
| Adams, R; Agus, A; Barnes, RA; Chau, I; Clarke, M; Coyle, V; Doran, A; Forde, C; Grayson, M; McAuley, DF; McDowell, C; McMullan, R; Plummer, R; Thomas, AL; Wilson, RH | 1 |
| Bruniera, FR; Costa, SF; Cury, AP; Higashino, H; Mendes, FR; Oliveira, FN; Rizeck, C; Rocha, V; Rossi, F; Schmidt, J | 1 |
| Carvalhaes, CG; Castanheira, M; Doyle, TB; Sader, HS; Streit, JM | 1 |
| Dorn, C; Hitzenbichler, F; Kees, F; Kees, M; Liebchen, U; Paal, M; Schiesser, S | 1 |
| Al-Shaer, MH; Alghamdi, WA; Peloquin, C | 1 |
| Bruno, C; Carmelitano, P; Castanheira, M; De Anda, C; Huntington, JA; Johnson, MG; Motyl, M; Rhee, EG; Yu, B | 1 |
| Sivashanmugam, K; Srivastava, P | 1 |
| Chatfield, MD; Harris, PNA; Littleford, R; Paterson, DL; Stewart, AG | 1 |
| Garcia, JA; Liang, SY; Long, B; Matlock, A; Moussavi, K | 1 |
| Krnáč, D; Reiffová, K; Rolinski, B | 1 |
| Barrio-Tofiño, ED; Cortes-Lara, S; López-Causapé, C; Oliver, A | 1 |
| Barreto, EF; Bjergum, MW; Jannetto, PJ; Rule, AD; Scheetz, MH | 1 |
| Bruno, CJ; Butterton, JR; Huntington, JA; Jensen, EH; Kivistik, Ü; Kollef, MH; Martin-Loeches, I; Nováček, M; Réa-Neto, Á; Rhee, EG; Shime, N; Timsit, JF; Wolf, DJ; Wunderink, RG; Yu, B | 1 |
| Boelens, J; De Waele, JJ; Polet, M; Stove, V; Van Vooren, S; Vanhaecke, L; Verstraete, AG | 1 |
| Burgess, DS; Clark, JA; Landmesser, KB | 1 |
| Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS | 1 |
| Albanell-Fernández, M; Aranda, L; Bartra, J; Gelis, S; González-García, R; López-Cabezas, C; Soy Muner, D | 1 |
| Chen, WT; DeRyke, CA; Kazmierczak, KM; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Attou, R; Barreto Gutierrez, L; Boer, W; De Bels, D; Gallerani, A; Honore, PM; Kaefer, K; Moorthamers, S; Preseau, T; Redant, S | 1 |
| Bruno, CJ; Butterton, JR; Gates, D; Huntington, JA; Jensen, EH; Kivistik, Ü; Kollef, MH; Lin, G; Martin-Loeches, I; Motyl, M; Nováček, M; Réa-Neto, Á; Rhee, EG; Shime, N; Timsit, JF; Wunderink, RG; Yu, B | 1 |
| Carvalhaes, CG; Castanheira, M; Mendes, RE; Sader, HS | 1 |
| Alonso-Ramos, H; Barrera-Cabeza, J; Cordero-Ramos, J; Fernández-Del-Castillo, SS; Hoxha, M; Moya-Martin, M; Murillo-Izquierdo, M; Nunez-Nunez, M; Oltra-Hostalet, F; Quesada Pérez, MT; Retamar-Gentil, P | 1 |
| Albur, M; Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
| Doogue, M; Jensen, BP; Mortensen, JS | 1 |
| Ju, YG; Lee, HJ; Lee, MG; Sohn, JW; Yim, HS; Yoon, YK | 1 |
| Birgy, A; Bonacorsi, S; Courroux, C; Danjean, M; Gits-Muselli, M; Hobson, CA; Monjault, A | 1 |
| Bassetti, M; Bruno, CJ; Castanheira, M; Huntington, JA; Jensen, EH; Johnson, MG; Motyl, M; Paterson, DL; Wolf, DJ; Yu, B | 1 |
| Güler, N; Süleyman, A; Tamay, Z | 1 |
| Babiak, P; Cizmarova, I; Kovac, A; Mikus, P; Parrak, V; Piestansky, J; Secnik, P | 1 |
| Bensaci, M; Bruno, CJ; Chen, G; Chen, X; Du, X; Fan, J; Huntington, JA; Johnson, MG; Sun, F; Sun, Y; Wang, H; Wang, Y | 1 |
| Castanheira, M; Chen, WT; Pfaller, M; Shortridge, D; Streit, J; Tulloch, M | 1 |
| Cheng, B; Guo, P; Jia, P; Xu, Y; Yang, Q; Zhang, H; Zhu, Y | 1 |
| Arenere-Mendoza, M; Fernández-de-Gamarra-Martínez, E; Fernández-Polo, A; González-Suárez, S; Gutiérrez-Urbón, JM; Nicolás-Picó, J; Rodríguez-Mateos, ME; Sánchez-Yáñez, E | 1 |
| Maseda, E; Suárez de la Rica, A | 1 |
| Bruno, CJ; Huntington, JA; Jensen, EH; Kollef, MH; Martin-Loeches, I; Timsit, JF; Wunderink, RG; Yu, B | 1 |
| Caljon, B; Crombé, F; De Geyter, D; Demuyser, T; Janssen, T; Muyldermans, A; Piérard, D; Seyler, L; Vanstokstraeten, R; Wybo, I | 1 |
| Ashouri, N; Bensaci, M; Bradley, JS; Bruno, CJ; De Anda, C; Huntington, JA; Johnson, MG; Lonchar, J; Popejoy, MW; Rhee, EG; Roilides, E; Su, FH | 1 |
| Arends, SJR; Carvalhaes, CG; Castanheira, M; Mendes, RE; Sader, HS; Shortridge, D | 1 |
| Bensaci, M; Bruno, CJ; De Anda, C; Dementieva, N; Huntington, JA; Jackson, CA; Johnson, MG; Lonchar, J; Newland, J; Popejoy, MW; Rhee, EG; Su, FH | 1 |
| Deng, T; Kong, W; Li, S; Shu, Y; Wu, Y | 1 |
| Chau, RWY; Chen, WT; DeRyke, CA; Ip, M; Karlowsky, JA; Khan, TK; Leung, SWM; Lob, SH; Motyl, MR; Sahm, DF; Seto, WH; Wong, QW; Woo, PCY; Young, K | 1 |
| Chen, CH; Ho, MW; Hsueh, PR; Ko, WC; Lin, HH; Tseng, KH; Wu, PH | 1 |
| Hsueh, PR; Lee, YL | 1 |
| Hsueh, PR; Ko, WC; Lee, YL | 1 |
| Demuyser, T; Echahidi, F; Olbrecht, M; Peeters, C; Piérard, D; Vandamme, P; Wybo, I | 1 |
| Chen, WT; DeRyke, CA; Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
10 review(s) available for tazobactam and meropenem
| Article | Year |
|---|---|
Role of pharmacodynamics in designing dosage regimens for beta-lactams.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Dose-Response Relationship, Drug; Humans; Meropenem; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2003 |
Antibiotic Dosing in Continuous Renal Replacement Therapy.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Computer Simulation; Critical Illness; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Renal Replacement Therapy; Sepsis; Tazobactam; Thienamycins | 2017 |
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Boronic Acids; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Meropenem; Tazobactam | 2019 |
The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Cephalosporins; Clinical Trials as Topic; Drug Combinations; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Humans; Meropenem; Tazobactam | 2019 |
Capnocytophaga sputigena bloodstream infection in hematopoietic stem cell transplantations: two cases report and review of the literature.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Capnocytophaga; Gram-Negative Bacterial Infections; Hematopoietic Stem Cell Transplantation; Humans; Meropenem; Middle Aged; Mucositis; Neutrophils; Piperacillin; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Tazobactam; Transplantation, Autologous | 2020 |
Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Design; Drug Resistance, Multiple; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Humans; Meropenem; Sisomicin; Tazobactam; Tetracyclines | 2021 |
Compatibility of prolonged infusion antibiotics during Y-site administration.
Topics: Anti-Bacterial Agents; Cefepime; Humans; Infusions, Intravenous; Meropenem; Tazobactam | 2022 |
Preanalytical Stability of Flucloxacillin, Piperacillin, Tazobactam, Meropenem, Cefalexin, Cefazolin, and Ceftazidime in Therapeutic Drug Monitoring: A Structured Review.
Topics: Anti-Bacterial Agents; Cefazolin; Ceftazidime; Cephalexin; Drug Monitoring; Drug Stability; Floxacillin; Humans; Meropenem; Piperacillin; Tazobactam | 2022 |
Controversies in the management of ESBL-producing Enterabacterales. Clinical Implications.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2022 |
Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Humans; Intraabdominal Infections; Meropenem; Metronidazole; Network Meta-Analysis; Tazobactam; Tigecycline | 2023 |
16 trial(s) available for tazobactam and meropenem
| Article | Year |
|---|---|
Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Topics: Amikacin; Anti-Bacterial Agents; Drug Therapy, Combination; Fever; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Hematologic Neoplasms; Humans; Infections; Meropenem; Neoplasms; Netilmicin; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2004 |
Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Male; Meropenem; Middle Aged; Neoplasms; Neutropenia; Opportunistic Infections; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Thienamycins | 2005 |
Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Fever; Humans; Immunocompromised Host; Male; Meropenem; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Risk Assessment; Risk Factors; Tazobactam; Thienamycins | 2006 |
Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.
Topics: Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Intraabdominal Infections; Male; Meropenem; Metronidazole; Middle Aged; Penicillanic Acid; Tazobactam; Thienamycins; Treatment Outcome | 2014 |
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Double-Blind Method; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Male; Meropenem; Metronidazole; Middle Aged; Penicillanic Acid; Tazobactam; Thienamycins; Treatment Outcome; Urinary Tract Infections; Young Adult | 2017 |
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Female; Humans; Male; Meropenem; Middle Aged; Pneumonia, Bacterial; Tazobactam; Treatment Outcome | 2019 |
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ciprofloxacin; Cost-Benefit Analysis; Drug Administration Schedule; Equivalence Trials as Topic; Humans; Meropenem; Multicenter Studies as Topic; Neoplasms; Neutropenia; Piperacillin; Pragmatic Clinical Trials as Topic; Quality of Life; Sepsis; Tazobactam; Treatment Outcome | 2020 |
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; DNA, Bacterial; Double-Blind Method; Drug Resistance, Bacterial; Healthcare-Associated Pneumonia; Humans; Meropenem; Multicenter Studies as Topic; Multilocus Sequence Typing; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Tazobactam; Treatment Outcome | 2021 |
Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferior
Topics: Adult; Anti-Bacterial Agents; Australia; beta-Lactamases; Cephalosporins; Clostridioides difficile; Escherichia coli; Humans; Italy; Lebanon; Meropenem; Microbial Sensitivity Tests; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Saudi Arabia; Sepsis; Singapore; Spain; Tazobactam | 2021 |
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Equivalence Trials as Topic; Female; Healthcare-Associated Pneumonia; Humans; Logistic Models; Male; Meropenem; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Tazobactam | 2021 |
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Tazobactam; Ventilators, Mechanical | 2022 |
Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Escherichia coli; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Retrospective Studies; Tazobactam; Ventilators, Mechanical | 2022 |
A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; China; Double-Blind Method; Humans; Intraabdominal Infections; Meropenem; Metronidazole; Tazobactam | 2022 |
Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Hospitals; Humans; Meropenem; Monobactams; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Tazobactam; Vasoconstrictor Agents; Ventilators, Mechanical | 2022 |
Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Child; Escherichia coli; Humans; Infant, Newborn; Meropenem; Penicillanic Acid; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2023 |
Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Child; Escherichia coli; Humans; Intraabdominal Infections; Meropenem; Metronidazole; Penicillanic Acid; Tazobactam | 2023 |
104 other study(ies) available for tazobactam and meropenem
| Article | Year |
|---|---|
Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
Topics: Acinetobacter; Acinetobacter Infections; Amino Acid Sequence; Anti-Bacterial Agents; Argentina; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Clavulanic Acid; Cloning, Molecular; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA | 2007 |
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cephalosporins; Chryseobacterium; Flavobacteriaceae Infections; Humans; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillins; Sequence Analysis, DNA | 2007 |
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
Topics: Aztreonam; beta-Lactamases; Carbapenems; Catalysis; Cephalosporins; Clavulanic Acid; Electrophoresis, Polyacrylamide Gel; Escherichia coli; Hydrolysis; Kinetics; Molecular Weight; Penicillanic Acid; Penicillins; Recombinant Proteins; Serratia; Sulbactam; Tazobactam | 2007 |
First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
Topics: Aeromonas; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; France; Integrons; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Sequence Analysis, DNA; Substrate Specificity | 2007 |
Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; beta-Lactamases; Brachyspira; Cloning, Molecular; Diarrhea; Feces; Gram-Negative Bacterial Infections; Humans; Kinetics; Molecular Sequence Data; Oxacillin; Penicillin Resistance; Sequence Analysis, DNA | 2008 |
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
Topics: Acremonium; Bacterial Proteins; beta-Lactamases; Catalysis; Catalytic Domain; Cefepime; Ceftazidime; Cephalosporins; Kinetics; Models, Molecular; Mutation; Penicillinase; Protein Structure, Tertiary; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity | 2008 |
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Risk Factors; Treatment Failure | 2008 |
Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
Topics: Alleles; Amino Acid Sequence; Amino Acid Substitution; Base Sequence; beta-Lactamases; Burkholderia cepacia complex; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Hydrolysis; Isoelectric Point; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Plasmids; Sequence Analysis, DNA; Sequence Homology, Amino Acid | 2009 |
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
Topics: Acetylation; Acetyltransferases; Aminoglycosides; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Integrons; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2009 |
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
Topics: Amino Acid Sequence; Amoxicillin; Ampicillin; Animals; Anti-Bacterial Agents; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Blotting, Southern; Campylobacter jejuni; Carbenicillin; Cephalosporins; Chickens; Cloxacillin; Isoelectric Focusing; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillins; Piperacillin; Polymerase Chain Reaction; Sequence Alignment; Ticarcillin | 2009 |
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Blotting, Southern; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; France; Fresh Water; Gram-Negative Bacteria; Health Surveys; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Pseudomonas fluorescens; Water Microbiology | 2010 |
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; beta-Lactams; Cephalosporins; Genetic Variation; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2010 |
KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
Topics: Aged; beta-Lactamases; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Klebsiella Infections; Klebsiella pneumoniae; Male; Renal Dialysis; Republic of Korea | 2010 |
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
Topics: Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cephalosporinase; Clavulanic Acid; Computer Simulation; Enzyme Inhibitors; Hydrogen Bonding; Kinetics; Microbial Sensitivity Tests; Molecular Structure; Mutagenesis, Site-Directed; Penicillanic Acid; Protein Structure, Secondary; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity; Sulbactam; Tazobactam | 2010 |
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
Topics: Ampicillin; beta-Lactamases; Computational Biology; Escherichia coli; Hydrogen Bonding; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Protein Structure, Secondary; Ticarcillin | 2010 |
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Boronic Acids; Carbapenems; Crystallography, X-Ray; Drug Resistance, Bacterial; Drug Synergism; Gram-Negative Bacteria; Heterocyclic Compounds, 1-Ring; Mice; Microbial Sensitivity Tests; Models, Molecular; Rats; Stereoisomerism; Structure-Activity Relationship | 2015 |
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactam Resistance; beta-Lactamase Inhibitors; Borinic Acids; Carbapenems; Carboxylic Acids; Humans; Mice; Models, Molecular | 2020 |
Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Drug Synergism; Enzyme Inhibitors; Imipenem; Meropenem; Microbial Sensitivity Tests; Monobactams; Penicillanic Acid; Piperacillin; Porins; Pseudomonas aeruginosa; Tazobactam; Thienamycins | 1997 |
Carbapenemase-producing Pseudomonas aeruginosa in UK.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Enzyme Inhibitors; Gentamicins; Humans; Imipenem; Meropenem; Metalloproteins; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; United Kingdom | 1998 |
In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Topics: Acinetobacter; Anti-Bacterial Agents; Austria; beta-Lactam Resistance; Carbapenems; Cephalosporins; Enterobacteriaceae; Humans; Imipenem; In Vitro Techniques; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonadaceae; Tazobactam; Thienamycins | 1999 |
Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Critical Care; Cystic Fibrosis; Data Collection; Drug Resistance, Bacterial; Europe; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Population Surveillance; Proteus Infections; Proteus mirabilis; Tazobactam; Thienamycins | 2002 |
In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Culture Media, Conditioned; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Tazobactam; Thienamycins | 2004 |
[Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Ceftazidime; Ciprofloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; Ticarcillin | 2004 |
[The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Oxazines; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Thienamycins | 2006 |
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Clavulanic Acid; Gentamicins; Humans; Imipenem; Integrons; Meropenem; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam; Thienamycins | 2009 |
Comparative in vitro study of the antimicrobial activities of different commercial antibiotic products for intravenous administration.
Topics: Animals; Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; Campylobacter Infections; Drug Resistance; Drug Resistance, Multiple, Bacterial; Humans; Infusions, Intravenous; Injections, Intravenous; Meropenem; Mice; Mice, Inbred BALB C; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins; Tissue Distribution | 2010 |
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Sepsis; Shock, Septic; Tazobactam; Thienamycins | 2010 |
Importance of infusion volume and pump characteristics in extended administration of ß-lactam antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Drug Administration Routes; Humans; Meropenem; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2010 |
Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cost-Benefit Analysis; Critical Care; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Markov Chains; Meropenem; Middle Aged; Models, Economic; Penicillanic Acid; Piperacillin; Pneumonia; Quality-Adjusted Life Years; Tazobactam; Thienamycins; Treatment Failure; United Kingdom | 2012 |
Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Clavulanic Acid; Enzyme Inhibitors; Escherichia coli Proteins; Kinetics; Meropenem; Molecular Dynamics Simulation; Molecular Structure; Penicillanic Acid; Spectrometry, Mass, Electrospray Ionization; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sulbactam; Tazobactam; Thienamycins | 2011 |
Class A carbapenemase FPH-1 from Francisella philomiragia.
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Doripenem; Ertapenem; Escherichia coli; Francisella; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam; Thienamycins | 2012 |
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Ciprofloxacin; Critical Illness; Female; Hemofiltration; Humans; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins; Vancomycin | 2012 |
Case-control study of drug monitoring of β-lactams in obese critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Case-Control Studies; Cefepime; Ceftazidime; Cephalosporins; Drug Monitoring; Enzyme Inhibitors; Female; Humans; Male; Meropenem; Middle Aged; Obesity; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy; Sepsis; Shock, Septic; Tazobactam; Thienamycins; Young Adult | 2013 |
Postoperative bacteriuria, pyuria and urinary tract infection in patients with an orthotopic sigmoid colon neobladder replacement.
Topics: Aged; Anti-Bacterial Agents; Bacteriuria; Cefepime; Cephalosporins; Colon, Sigmoid; Cystectomy; Drug Resistance, Multiple, Bacterial; Enterococcus; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Leukocyte Count; Levofloxacin; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Postoperative Complications; Prevalence; Pyuria; Staphylococcus aureus; Sulfamethoxazole; Tazobactam; Thienamycins; Trimethoprim; Urinary Diversion; Urinary Tract Infections | 2014 |
Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2014 |
Quantification of piperacillin, tazobactam, meropenem, ceftazidime, and linezolid in human plasma by liquid chromatography/tandem mass spectrometry.
Topics: Adult; Anti-Bacterial Agents; Ceftazidime; Child; Chromatography, Liquid; Drug Monitoring; Humans; Limit of Detection; Linezolid; Meropenem; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Tandem Mass Spectrometry; Tazobactam; Thienamycins | 2015 |
Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation.
Topics: Analytic Sample Preparation Methods; Anti-Bacterial Agents; Automation; Blood Chemical Analysis; Cefepime; Cephalosporins; Chromatography, High Pressure Liquid; Ciprofloxacin; Humans; Isotopes; Linezolid; Meropenem; Penicillanic Acid; Piperacillin; Tandem Mass Spectrometry; Tazobactam; Thienamycins; Time Factors | 2015 |
Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital.
Topics: Anti-Infective Agents; Bacteroides fragilis; Bacteroides Infections; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Inhibitory Concentration 50; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Republic of Korea; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tazobactam; Tertiary Care Centers; Thienamycins | 2015 |
Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Drug Combinations; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; United States | 2015 |
Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA.
Topics: Allosteric Regulation; Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Drug Synergism; Drug Therapy, Combination; Female; Gene Expression; Humans; Linezolid; Meropenem; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Operon; Penicillanic Acid; Penicillin-Binding Proteins; Piperacillin; Staphylococcal Infections; Tazobactam; Thienamycins | 2015 |
A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Prospective Studies; Sulbactam; Tazobactam; Thienamycins | 2015 |
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
Topics: Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Thienamycins | 2016 |
An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ciprofloxacin; Ertapenem; Escherichia coli; Female; Gentamicins; Humans; Immunocompromised Host; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Thienamycins; Tobramycin | 2016 |
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin | 2017 |
Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Tazobactam; Thienamycins | 2017 |
In vitro activity of ceftolozane/tazobactam in combination with other classes of antibacterial agents.
Topics: Amikacin; Aztreonam; Cephalosporins; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Tazobactam; Tigecycline | 2017 |
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Catheter-Related Infections; Ceftazidime; Cephalosporins; Cross Infection; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Antibiotics susceptibility patterns of uropathogenic E. coli with special reference to fluoroquinolones in different age and gender groups.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Cefoperazone; Child; Child, Preschool; Cross-Sectional Studies; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Imipenem; Infant; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Sulbactam; Tazobactam; Urinary Tract Infections; Young Adult | 2017 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Humans; Iatrogenic Disease; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tazobactam; Thienamycins; Tobramycin | 2017 |
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Los Angeles; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Optimizing Empiric Antibiotic Selection in Sepsis: Turning Probabilities Into Practice.
Topics: Anti-Bacterial Agents; Bacteremia; Cefepime; Gram-Negative Bacteria; Humans; Meropenem; Probability; Sepsis; Tazobactam | 2018 |
Reply to MacFadden et al.
Topics: Bacteremia; Cefepime; Gram-Negative Bacteria; Humans; Meropenem; Piperacillin; Sepsis; Tazobactam | 2018 |
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazoba
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2018 |
Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates.
Topics: Bacteremia; Cephalosporins; Drug Resistance, Bacterial; Humans; Immunocompromised Host; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Gene Expression; Hospitalization; Humans; Isoenzymes; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Plasmids; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Retrospective Studies; Tazobactam; United States | 2018 |
Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 2: Stability Evaluation.
Topics: Anti-Bacterial Agents; Cefepime; Chromatography, Liquid; Drug Stability; Humans; Meropenem; Piperacillin; Tandem Mass Spectrometry; Tazobactam; Temperature | 2018 |
Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Chromatography, Liquid; Humans; Meropenem; Piperacillin; Sensitivity and Specificity; Tandem Mass Spectrometry; Tazobactam | 2018 |
Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.
Topics: Anti-Bacterial Agents; Cefepime; Critical Illness; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Tazobactam | 2018 |
Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Load; beta-Lactamase Inhibitors; Cephalosporins; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Models, Theoretical; Tazobactam | 2018 |
Antibiotics for Ceftriaxone-Resistant Gram-Negative Bacterial Bloodstream Infections.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Tazobactam | 2019 |
Antibiotics for Ceftriaxone-Resistant Gram-Negative Bacterial Bloodstream Infections.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Tazobactam | 2019 |
Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem.
Topics: Acute Kidney Injury; Aged; Cefepime; Critical Illness; Female; Humans; Incidence; Male; Meropenem; Middle Aged; Multivariate Analysis; Piperacillin; Retrospective Studies; Tazobactam; Vancomycin | 2019 |
Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Fosfomycin; Humans; Meropenem; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin; United States | 2019 |
Stability Studies of Antipyocyanic Beta-Lactam Antibiotics Used in Continuous Infusion.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Imipenem; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2019 |
Preanalytical Stability of Piperacillin, Tazobactam, Meropenem, and Ceftazidime in Plasma and Whole Blood Using Liquid Chromatography-Tandem Mass Spectrometry.
Topics: Anti-Bacterial Agents; Ceftazidime; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Meropenem; Piperacillin; Plasma; Tandem Mass Spectrometry; Tazobactam | 2019 |
Activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata - SMART United States 2016-2017.
Topics: Abdomen; Adult; Aged; Ceftazidime; Cephalosporins; Female; Humans; Levofloxacin; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Respiratory System; Tazobactam; United States; Urinary Tract | 2020 |
Can ceftolozane-tazobactam treat nosocomial pneumonia?
Topics: Cephalosporins; Cross Infection; Double-Blind Method; Humans; Meropenem; Pneumonia; Tazobactam | 2019 |
Topics: Achromobacter; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Burkholderia; Cystic Fibrosis; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Stenotrophomonas; Stenotrophomonas maltophilia; Tazobactam | 2019 |
In vitro activity of meropenem/piperacillin/tazobactam triple combination therapy against clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus pseudintermedius and vancomycin-resistant Enterococcus spp.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Genome, Bacterial; Genomics; Humans; Meropenem; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Piperacillin; Staphylococcal Infections; Staphylococcus; Staphylococcus epidermidis; Tazobactam; Vancomycin-Resistant Enterococci; Whole Genome Sequencing | 2020 |
Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia - Authors' reply.
Topics: Cephalosporins; Cross Infection; Doripenem; Double-Blind Method; Humans; Meropenem; Pneumonia, Ventilator-Associated; Tazobactam | 2020 |
Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia.
Topics: Cephalosporins; Cross Infection; Doripenem; Double-Blind Method; Humans; Meropenem; Pneumonia, Ventilator-Associated; Tazobactam | 2020 |
Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Infections; Ceftazidime; Cephalosporins; Cost-Benefit Analysis; Drug Combinations; Hospitalization; Humans; Intraabdominal Infections; Italy; Meropenem; Models, Economic; Tazobactam | 2019 |
Antimicrobial susceptibility of plastic-associated bacteria isolated from the ocean to novel antibiotics (delafloxacin, meropenem/vaborbactam, ceftolozane/tazobactam, ceftobiprole) - Can environmental bacteria be predictors of persistence of antibiotic ac
Topics: Antarctic Regions; Anti-Bacterial Agents; Bacteria; Boronic Acids; Cephalosporins; Drug Resistance, Microbial; Fluoroquinolones; Islands; Meropenem; Oceans and Seas; Plastics; Polystyrenes; Tazobactam | 2020 |
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Germany; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phenotype; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam; United States; Whole Genome Sequencing | 2021 |
Comment on "Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples".
Topics: Anti-Bacterial Agents; Cefepime; Humans; Meropenem; Piperacillin; Protein Binding; Tazobactam | 2020 |
Comment on "Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples".
Topics: Anti-Bacterial Agents; Cefepime; Humans; Meropenem; Piperacillin; Protein Binding; Tazobactam | 2020 |
Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Diabetic Foot; Drug Resistance; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
A new HPLC-MS/MS analytical method for quantification of tazobactam, piperacillin, and meropenem in human plasma.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Limit of Detection; Meropenem; Piperacillin; Plasma; Reproducibility of Results; Tandem Mass Spectrometry; Tazobactam | 2021 |
Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Meropenem; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Stability and Validation of a High-Throughput LC-MS/MS Method for the Quantification of Cefepime, Meropenem, and Piperacillin and Tazobactam in Serum.
Topics: Cefepime; Chromatography, Liquid; Humans; Meropenem; Piperacillin; Reproducibility of Results; Tandem Mass Spectrometry; Tazobactam | 2021 |
Development and validation of a liquid chromatography high-resolution mass spectrometry orbitrap method for the sensitive quantification of amoxicillin, piperacillin, tazobactam and meropenem in human faeces.
Topics: Amoxicillin; Anti-Bacterial Agents; Chromatography, Liquid; Feces; Humans; Mass Spectrometry; Meropenem; Piperacillin; Research Design; Tazobactam | 2021 |
Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Critical Illness; Humans; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam | 2021 |
Evaluation of desensitization protocols to betalactam antibiotics.
Topics: Anti-Bacterial Agents; Ceftazidime; Ceftriaxone; Drug Hypersensitivity; Humans; Meropenem; Reproducibility of Results; Retrospective Studies; Review Literature as Topic; Tazobactam | 2022 |
In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Meropenem; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Thailand | 2022 |
Comparison between meropenem and ceftolozane/tazobactam: possible influence of CRRT.
Topics: Cephalosporins; Humans; Meropenem; Tazobactam | 2022 |
Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam | 2022 |
Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Ceftazidime; Cephalosporins; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Monobactams; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Colistin; Drug Combinations; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Rifampin; Tazobactam; Tigecycline | 2022 |
Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Humans; Imipenem; Meropenem; Tazobactam | 2022 |
Antibiotic allergy in children with cystic fibrosis: A retrospective case-control study.
Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Case-Control Studies; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Humans; Levofloxacin; Meropenem; Piperacillin; Retrospective Studies; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
An Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Determination of 4 β-Lactam Antibiotics, Tazobactam, and Linezolid in Human Plasma Samples.
Topics: Anti-Bacterial Agents; Cefepime; Cefotaxime; Chromatography, High Pressure Liquid; Critical Illness; Drug Monitoring; Humans; Linezolid; Meropenem; Monobactams; Piperacillin; Reproducibility of Results; Tandem Mass Spectrometry; Tazobactam | 2022 |
Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Meropenem; Microbial Sensitivity Tests; New Zealand; Penicillanic Acid; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam | 2022 |
In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
Topics: Ampicillin; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftaroline; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Imipenem; Klebsiella pneumoniae; Levofloxacin; Meropenem; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Piperacillin; Tazobactam; Tigecycline | 2022 |
PAUSATE Study: Prevalence and appropriateness of the use of antimicrobials in Spanish hospitals.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Clavulanic Acid; Cross-Sectional Studies; Hospitals; Humans; Meropenem; Piperacillin; Prevalence; Tazobactam | 2022 |
Genotypic resistance determined by whole genome sequencing versus phenotypic resistance in 234 Escherichia coli isolates.
Topics: Amikacin; Amoxicillin; Anti-Bacterial Agents; Cefepime; Cefotaxime; Ceftazidime; Ciprofloxacin; Clavulanic Acid; Escherichia coli; Escherichia coli Infections; Genotype; Gentamicins; Humans; Meropenem; Microbial Sensitivity Tests; Phenotype; Piperacillin; Retrospective Studies; Tazobactam; Tobramycin; Whole Genome Sequencing | 2023 |
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Hospitals; Humans; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ertapenem; Escherichia coli; Hong Kong; Humans; Imipenem; Intensive Care Units; Meropenem; Pseudomonas aeruginosa; Tazobactam | 2023 |
Geographic patterns of antimicrobial susceptibilities for Bacteroides spp. worldwide: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2007-2020.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteroides fragilis; Bacteroides Infections; Cefoxitin; Clindamycin; Humans; Leadership; Meropenem; Microbial Sensitivity Tests; Piperacillin; Tazobactam; Tigecycline | 2023 |
Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Topics: Achromobacter; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Tazobactam | 2023 |
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thailand | 2023 |